Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by 404c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.79, $4.04 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $6.29 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Vistance Networks sells Ruckus Networks to Belden for ~$1.75B net
• Snail, Inc. sets 1-for-5 reverse stock split to meet Nasdaq rules